Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats
BACKGROUND AND AIMS Portal hypertension is the main consequence of cirrhosis, responsible for the complications defining clinical decompensation. The only cure for decompensated cirrhosis is liver transplantation, but it is a limited resource and opens the possibility of regenerative therapy. We investigated the potential of primary human amniotic membrane-derived mesenchymal stromal (hAMSCs) and epithelial (hAECs) stem cells for the treatment of portal hypertension and decompensated cirrhosis. METHODS In vitro: Primary liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs) from cirrhotic rats (chronic CCl4 inhalation) were co-cultured with hAMSCs, hAECs or vehicle for…
Umbilical cord versus bone marrow-derived mesenchymal stromal cells.
incetheplacentaisapostnatal tissue and discarded asmedical waste, harvesting stem cells from this organrepresents a noninvasive and ethically conductive proce-dure. Perinatal stem cells isolated from amnion, chorion,umbilical cord, and cord blood are increasingly viewedas reliable sources of mesenchymal stromal cells (MSCs)alternative to bone marrow-derived ones (BM-MSCs),which are currently the most commonly used in clinicalapplications [1–5].Perinatal stem cells are a bridge between embryonic stemcells (ESCs) and adult stem cells (such as BM-MSCs). Theyshare many characteristics of both cells [1,6]. Considering thestructural complexity of the term ‘‘placenta,’’ we have fo-cused our attent…